Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Dominica Health Times.
Press releases published on October 23, 2025
eteraflex connects and CliniExperts Announce Global Alliance to Redefine Clinical Research and Regulatory Services Delivery
Princeton, NJ, Oct. 23, 2025 (GLOBE NEWSWIRE) -- eteraflex connects and CliniExperts have announced a strategic partnership that unites their complementary expertise in clinical research, regulatory strategy, and technology integration under a single, …
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.
Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: €586.5 million, down 2.8% at CER1 and on a like-for-like basis2, largely due to the fall in activity in France An increase in Q3 of 2.6% at CER and on a like-for-like basis, …
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.
Chiffre d’affaires au 30 septembre 2025 Retour de la croissance au 3ème trimestre 2025 Chiffre d’affaires à 9 mois : 586,5 M€, en retrait de 2,8% à TCC1 et périmètre comparable2, largement dû à la baisse de l’activité en France Au troisième …
Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts
Company honored by state’s Legislative Manufacturing Caucus for outstanding leadership and contributions to the manufacturing sector State-of-the-art production line is bringing in new clients, new projects, new indications LAUPHEIM, Germany and MILFORD, …
Roxanna Gapstur, Ph.D., R.N., WellSpan president and CEO, named a Distinguished Daughter of PA
York, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- WellSpan Health president and CEO Roxanna Gapstur, Ph.D., R.N., has been named one of nine women inductees as a Distinguished Daughter of Pennsylvania for 2025. Gapstur was recognized recently at an event …
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, …
BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025
LONG BEACH, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report third quarter 2025 financial results after market close on Thursday, November 6, 2025. The …
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence …
CHESS Health and Diamond Mind Partner to Deliver Groundbreaking Veteran-Focused Support
Rochester, New York, Oct. 23, 2025 (GLOBE NEWSWIRE) -- CHESS Health, a leading provider of evidence-based digital health solutions for substance use disorder (SUD), today announced a partnership with Garret Biss of Diamond Mind, LLC to deliver culturally …
Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services
NEWTOWN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT or the “Company”) announced that it has entered into agreements with Helius and Twinstake (each, a “Provider,” and collectively, the “Providers”), related to non-custodial staking …
BBG Advanced Therapies collects first cell donation on one-of-a-kind bus
San Antonio, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare. The BBG Advanced Therapies mobile leukapheresis …
Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide
ESTERO, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Visory Health, a patient-first health tech prescription platform that is transforming the way veterans, families and caregivers access affordable healthcare through its prescription discount card, today …
Synfini Selected for SLAS 2026 Innovation AveNEW Showcase
MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Synfini, Inc., provider of the industry’s most innovative Agile AI Foundry for drug discovery, today announced it has been chosen for the prestigious Innovation AveNEW showcase at the Society for …
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
MELBOURNE, Australia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has started a preclinical animal trial evaluating …
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening patients for Cohort 4; anticipate initiation …
Global Drug Delivery Systems (DDS) Market Transforms Amid New Pharma Demands
FRAMINGHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Alira Health today released its 2025 Global Drug Delivery System Trends Report, highlighting the rapid evolution of the global drug delivery systems (DDS) market. The report reveals how digital …
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, …
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a first-in-class oral anabolic treatment option that could …
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
Significant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to commence before year-end SARASOTA, FL, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO …
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG. New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%. Closing …